Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/TCRγδ+) and DERL-7 (CD56+/CD3−/TCRγδ−), derived from a single patient with CD56+ non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/TCRγδ+) and DERL-7 (CD56+/CD3−/TCRγδ−), derived from a single patient with CD56+ non-Hodgkin's lymphoma

Published:2001-10 Issue:10 Volume:15 Page:1641-1649
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Noto R Di,Pane F,Camera A,Luciano L,Barone M,Pardo C Lo,Boccuni P,Intrieri M,Izzo B,Villa MR,Macrí M,Rotoli B,Sacchetti L,Salvatore F,Del Vecchio L

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2402239.pdf

Reference47 articles.

1. Spits WH, Lanier LL, Phillips JH . Development of human T and natural killer cells Blood 1995 85: 2654–2670

2. Robertson MJ, Ritz J . Biology and clinical relevance of human natural killer cells Blood 1990 76: 2421–2438

3. Jaffe ES . Classification of natural killer (NK) cell and NK-like T-cell malignancies Blood 1996 87: 1207–1210

4. Loughran TP Jr . Clonal disease of large granular lymphocytes Blood 1993 82: 1–14

5. Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, Cheung MM, Lau WH . Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm Blood 1997 89: 4501–4513

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DERL2 (derlin 2) stabilizes BAG6 (BAG cochaperone 6) in chemotherapy resistance of cholangiocarcinoma;Journal of Physiology and Biochemistry;2023-10-10

2. Myc controls NK cell development, IL-15-driven expansion, and translational machinery;Life Science Alliance;2023-04-27

3. Myc controls IL-15-driven expansion and translational machinery of NK cells;2022-12-20

4. Cancer Cell Lines Are Useful Model Systems for Medical Research;Cancers;2019-08-01

5. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target;Nature Communications;2018-04-19